| Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial CS Fuchs, T Doi, RW Jang, K Muro, T Satoh, M Machado, W Sun, SI Jalal, ... JAMA oncology 4 (5), e180013-e180013, 2018 | 1623 | 2018 |
| Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study GK Abou-Alfa, V Sahai, A Hollebecque, G Vaccaro, D Melisi, R Al-Rajabi, ... The Lancet Oncology 21 (5), 671-684, 2020 | 1164 | 2020 |
| Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial K Muro, HC Chung, V Shankaran, R Geva, D Catenacci, S Gupta, JP Eder, ... The lancet oncology 17 (6), 717-726, 2016 | 1128 | 2016 |
| Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study GK Abou-Alfa, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ... The Lancet Oncology 21 (6), 796-807, 2020 | 739 | 2020 |
| Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer AB Schrock, C Ouyang, J Sandhu, E Sokol, D Jin, JS Ross, VA Miller, ... Annals of Oncology 30 (7), 1096-1103, 2019 | 556 | 2019 |
| Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer DVT Catenacci, MR Junttila, T Karrison, N Bahary, MN Horiba, SR Nattam, ... Journal of Clinical Oncology 33 (36), 4284, 2015 | 506 | 2015 |
| New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing JS Ross, K Wang, L Gay, R Al-Rohil, JV Rand, DM Jones, HJ Lee, ... The oncologist 19 (3), 235-242, 2014 | 491 | 2014 |
| Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution S Ling, Z Hu, Z Yang, F Yang, Y Li, P Lin, K Chen, L Dong, L Cao, Y Tao, ... Proceedings of the National Academy of Sciences 112 (47), E6496-E6505, 2015 | 386 | 2015 |
| Biliary cancer: utility of next‐generation sequencing for clinical management M Javle, T Bekaii‐Saab, A Jain, Y Wang, RK Kelley, K Wang, HC Kang, ... Cancer 122 (24), 3838-3847, 2016 | 361 | 2016 |
| Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised … DVT Catenacci, NC Tebbutt, I Davidenko, AM Murad, SE Al-Batran, ... The lancet oncology 18 (11), 1467-1482, 2017 | 324 | 2017 |
| Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma E Pectasides, MD Stachler, S Derks, Y Liu, S Maron, M Islam, L Alpert, ... Cancer discovery 8 (1), 37-48, 2018 | 271 | 2018 |
| Assessment of pembrolizumab therapy for the treatment of microsatellite instability–high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE … J Chao, CS Fuchs, K Shitara, J Tabernero, K Muro, E Van Cutsem, ... JAMA oncology 7 (6), 895-902, 2021 | 246 | 2021 |
| Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial AX Zhu, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ... JAMA oncology 7 (11), 1669-1677, 2021 | 237 | 2021 |
| Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the … YJ Bang, YK Kang, DV Catenacci, K Muro, CS Fuchs, R Geva, H Hara, ... Gastric Cancer 22, 828-837, 2019 | 233 | 2019 |
| Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition GS Wong, J Zhou, JB Liu, Z Wu, X Xu, T Li, D Xu, SE Schumacher, ... Nature medicine 24 (7), 968-977, 2018 | 232 | 2018 |
| Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer MA Shah, ZA Wainberg, DVT Catenacci, HS Hochster, J Ford, P Kunz, ... PloS one 8 (3), e54014, 2013 | 227 | 2013 |
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): A single-arm, phase 1b–2 trial DVT Catenacci, YK Kang, H Park, HE Uronis, KW Lee, MCH Ng, ... The lancet oncology 21 (8), 1066-1076, 2020 | 214* | 2020 |
| A phase I study of FOLFIRINOX plus IPI-926, a hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma AH Ko, N LoConte, MA Tempero, EJ Walker, RK Kelley, S Lewis, ... Pancreas 45 (3), 370-375, 2016 | 210 | 2016 |
| Treatment of locally advanced esophageal carcinoma: ASCO guideline MA Shah, EB Kennedy, DV Catenacci, DC Deighton, KA Goodman, ... Journal of Clinical Oncology 38 (23), 2677-2694, 2020 | 204 | 2020 |
| KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. CS Fuchs, T Doi, RWJ Jang, K Muro, T Satoh, M Machado, W Sun, ... Journal of Clinical Oncology 35 (15_suppl), 4003-4003, 2017 | 204 | 2017 |
